Table of Contents
1. REPORT PROLOGUE
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Primary Research
3.3. Secondary Research
3.4. Market Size Estimation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Porter’s Five Forces Analysis
5.1.1. Bargaining Power of Suppliers
5.1.2. Bargaining Power of Buyers
5.1.3. Threat of New Entrants
5.1.4. Threat of Substitutes
5.1.5. Intensity of Rivalry
5.2. Value Chain Analysis
6. GLOBAL MIGRAINE DRUGS MARKET, BY TYPE
6.1. Overview
6.2. Episodic Migraine
6.2.1. Market Estimates & Forecast, by Region, 2023-2032
6.2.2. Market Estimates & Forecast, by Country, 2023-2032
6.3. Chronic Migraine
6.3.1. Market Estimates & Forecast, by Region, 2023-2032
6.3.2. Market Estimates & Forecast, by Country, 2023-2032
7. GLOBAL MIGRAINE DRUGS MARKET, BY TREATMENT TYPE
7.1. Overview
7.2. Acute
7.2.1. Market Estimates & Forecast, by Region, 2023-2032
7.2.2. Market Estimates & Forecast, by Country, 2023-2032
7.3. Preventive
7.3.1. Market Estimates & Forecast, by Region, 2023-2032
7.3.2. Market Estimates & Forecast, by Country, 2023-2032
7.4. Neuromodulation
7.4.1. Market Estimates & Forecast, by Region, 2023-2032
7.4.2. Market Estimates & Forecast, by Country, 2023-2032
7.5. Others
8. GLOBAL MIGRAINE DRUGS MARKET, BY DRUG CLASS
8.1. Overview
8.2. Beta Blockers
8.2.1. Market Estimates & Forecast, by Region, 2023-2032
8.2.2. Market Estimates & Forecast, by Country, 2023-2032
8.3. Angiotensin Blockers
8.3.1. Market Estimates & Forecast, by Region, 2023-2032
8.3.2. Market Estimates & Forecast, by Country, 2023-2032
8.4. Tricyclics
8.4.1. Market Estimates & Forecast, by Region, 2023-2032
8.4.2. Market Estimates & Forecast, by Country, 2023-2032
8.5. Anticonvulsants
8.5.1. Market Estimates & Forecast, by Region, 2023-2032
8.5.2. Market Estimates & Forecast, by Country, 2023-2032
8.6. Triptans
8.6.1. Market Estimates & Forecast, by Region, 2023-2032
8.6.2. Market Estimates & Forecast, by Country, 2023-2032
8.7. Others
9. GLOBAL MIGRAINE DRUGS MARKET, BY END USER
9.1. Overview
9.2. Hospitals and Clinics
Market Estimates & Forecast, by Region, 2023-2032
Market Estimates & Forecast, by Country, 2023-2032
9.3. Retail Pharmacy
Market Estimates & Forecast, by Region, 2023-2032
Market Estimates & Forecast, by Country, 2023-2032
9.4. Online Pharmacy
Market Estimates & Forecast, by Region, 2023-2032
Market Estimates & Forecast, by Country, 2023-2032
9.5. Others
Market Estimates & Forecast, by Region, 2023-2032
Market Estimates & Forecast, by Country, 2023-2032
10. GLOBAL MIGRAINE DRUGS MARKET, BY REGION
10.1. Overview
10.2. Americas
10.2.1. North America
10.2.1.1. US
10.2.1.2. Canada
10.2.2. Latin America
10.3. Europe
10.3.1. Western Europe
10.3.1.1. Germany
10.3.1.2. France
10.3.1.3. UK
10.3.1.4. Italy
10.3.1.5. Spain
10.3.1.6. Rest of Western Europe
10.3.2. Eastern Europe
10.4. Asia-Pacific
10.4.1. China
10.4.2. India
10.4.3. Japan
10.4.4. Australia
10.4.5. South Korea
10.4.6. Rest of Asia-Pacific
10.5. Middle East & Africa
10.5.1. Middle East
10.5.2. Africa
11. COMPETITIVE LANDSCAPE
11.1. Introduction
11.2. Competitive Analysis
12. COMPANY PROFILES
12.1. Allergan Plc
12.1.1. Company Overview
12.1.2. Financial Overview
12.1.3. Product Offered
12.1.4. Key Developments
12.1.5. SWOT Analysis
12.1.6. Key Strategies
12.2. Alder Biopharmaceuticals, Inc.
12.2.1. Company Overview
12.2.2. Financial Overview
12.2.3. Product Offered
12.2.4. Key Developments
12.2.5. SWOT Analysis
12.2.6. Key Strategies
12.3. Pfizer Inc
12.3.1. Company Overview
12.3.2. Financial Overview
12.3.3. Product Offered
12.3.4. Key Developments
12.3.5. SWOT Analysis
12.3.6. Key Strategies
12.4. GlaxoSmithKline Plc
12.4.1. Company Overview
12.4.2. Financial Overview
12.4.3. Product Offered
12.4.4. Key Developments
12.4.5. SWOT Analysis
12.4.6. Key Strategies
12.5. Merck & Co., Inc.
12.5.1. Company Overview
12.5.2. Financial Overview
12.5.3. Product Offered
12.5.4. Key Developments
12.5.5. SWOT Analysis
12.5.6. Key Strategies
12.6. Teva Pharmaceutical Industries Ltd
12.6.1. Company Overview
12.6.2. Financial Overview
12.6.3. Product Offered
12.6.4. Key Developments
12.6.5. SWOT Analysis
12.6.6. Key Strategies
12.7. AstraZeneca Plc
12.7.1. Company Overview
12.7.2. Financial Overview
12.7.3. Product Offered
12.7.4. Key Developments
12.7.5. SWOT Analysis
12.7.6. Key Strategies
12.8. Johnson & Johnson Services, Inc.
12.8.1. Company Overview
12.8.2. Financial Overview
12.8.3. Product Offered
12.8.4. Key Developments
12.8.5. SWOT Analysis
12.8.6. Key Strategies
12.9. Amgen Inc
12.9.1. Company Overview
12.9.2. Financial Overview
12.9.3. Product Offered
12.9.4. Key Developments
12.9.5. SWOT Analysis
12.9.6. Key Strategies
12.10. Eli Lilly and Company
12.10.1. Company Overview
12.10.2. Financial Overview
12.10.3. Product Offered
12.10.4. Key Developments
12.10.5. SWOT Analysis
12.10.6. Key Strategies
12.11. eNeura Inc.
12.11.1. Company Overview
12.11.2. Financial Overview
12.11.3. Product Offered
12.11.4. Key Developments
12.11.5. SWOT Analysis
12.11.6. Key Strategies
12.12. Others
13. APPENDIX
13.1.1. Discussion Blueprint
13.1.2. Related Reports
NOTE:
This table of content is tentative and subject to change as the research progresses.
ï‚¡ In section 10, only the top companies will be profiled. Each company will be profiled based on the Market Overview, Financials, Product Portfolio, Business Strategies, and Recent Developments parameters.
ï‚¡ Please note: The financial details of the company cannot be provided if the information is not available in the public domain and or from reliable sources.
LIST OF TABLES
TABLE 1 GLOBAL MIGRAINE DRUGS MARKET SYNOPSIS, 2023-2032
TABLE 2 GLOBAL MIGRAINE DRUGS MARKET ESTIMATES & FORECAST, 2023-2032 (USD MILLION)
TABLE 3 GLOBAL MIGRAINE DRUGS MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION)
TABLE 4 GLOBAL MIGRAINE DRUGS MARKET, BY DRUG CLASS, 2023-2032 (USD MILLION)
TABLE 5 GLOBAL MIGRAINE DRUGS MARKET, BY END USER, 2023-2032 (USD MILLION)
TABLE 6 GLOBAL MIGRAINE DRUGS MARKET, BY REGION, 2023-2032 (USD MILLION)
TABLE 7 NORTH AMERICA: MIGRAINE DRUGS MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION)
TABLE 8 NORTH AMERICA: MIGRAINE DRUGS MARKET, BY DRUG CLASS, 2023-2032 (USD MILLION)
TABLE 9 NORTH AMERICA MIGRAINE DRUGS MARKET, BY END USER, 2023-2032(USD MILLION)
TABLE 10 US: MIGRAINE DRUGS MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION)
TABLE 11 US: MIGRAINE DRUGS MARKET, BY DRUG CLASS, 2023-2032 (USD MILLION)
TABLE 12 US: MIGRAINE DRUGS MARKET, BY END USER, 2023-2032(USD MILLION)
TABLE 13 CANADA: MIGRAINE DRUGS MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION)
TABLE 14 CANADA: MIGRAINE DRUGS MARKET, BY DRUG CLASS, 2023-2032 (USD MILLION)
TABLE 15 CANADA: MIGRAINE DRUGS MARKET, BY END USER, 2023-2032(USD MILLION)
TABLE 16 LATIN AMERICA: MIGRAINE DRUGS MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION)
TABLE 17 LATIN AMERICA: MIGRAINE DRUGS MARKET, BY DRUG CLASS, 2023-2032 (USD MILLION)
TABLE 18 LATIN AMERICA: MIGRAINE DRUGS MARKET, BY END USER, 2023-2032(USD MILLION)
TABLE 19 EUROPE: MIGRAINE DRUGS MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION)
TABLE 20 EUROPE: MIGRAINE DRUGS MARKET, BY DRUG CLASS, 2023-2032 (USD MILLION)
TABLE 21 EUROPE: MIGRAINE DRUGS MARKET, BY END USER, 2023-2032(USD MILLION)
TABLE 22 WESTERN EUROPE: MIGRAINE DRUGS MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION)
TABLE 23 WESTERN EUROPE: MIGRAINE DRUGS MARKET, BY DRUG CLASS, 2023-2032 (USD MILLION)
TABLE 24 WESTERN EUROPE: MIGRAINE DRUGS MARKET, BY END USER, 2023-2032(USD MILLION)
TABLE 25 EASTERN EUROPE: MIGRAINE DRUGS MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION)
TABLE 26 EASTERN EUROPE: MIGRAINE DRUGS MARKET, BY DRUG CLASS, 2023-2032 (USD MILLION)
TABLE 27 EASTERN EUROPE: MIGRAINE DRUGS MARKET, BY END USER, 2023-2032(USD MILLION)
TABLE 28 ASIA-PACIFIC: MIGRAINE DRUGS MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION)
TABLE 29 ASIA-PACIFIC: MIGRAINE DRUGS MARKET, BY DRUG CLASS, 2023-2032 (USD MILLION)
TABLE 30 ASIA-PACIFIC: MIGRAINE DRUGS MARKET, BY END USER, 2023-2032(USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA: MIGRAINE DRUGS MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA: MIGRAINE DRUGS MARKET, BY DRUG CLASS, 2023-2032 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA: MIGRAINE DRUGS MARKET, BY END USER, 2023-2032(USD MILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL MIGRAINE DRUGS MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL MIGRAINE DRUGS MARKET
FIGURE 4 GLOBAL MIGRAINE DRUGS MARKET SHARE, BY TREATMENT TYPE, 2020 (%)
FIGURE 5 GLOBAL MIGRAINE DRUGS MARKET SHARE, BY DRUG CLASS, 2020 (%)
FIGURE 6 GLOBAL MIGRAINE DRUGS MARKET SHARE, BY END USER, 2020(%)
FIGURE 7 GLOBAL MIGRAINE DRUGS MARKET SHARE, BY REGION, 2020 (%)
FIGURE 8 AMERICAS: MIGRAINE DRUGS MARKET SHARE BY REGION, 2020 (%)
FIGURE 9 NORTH AMERICA: MIGRAINE DRUGS MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 10 EUROPE: MIGRAINE DRUGS MARKET SHARE, BY REGION, 2020 (%)
FIGURE 11 WESTERN EUROPE: MIGRAINE DRUGS MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 12 ASIA-PACIFIC: MIGRAINE DRUGS MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 13 MIDDLE EAST & AFRICA: MIGRAINE DRUGS MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 14 GLOBAL MIGRAINE DRUGS MARKET: COMPANY SHARE ANALYSIS, 2020 (%)
FIGURE 15 ALLERGAN PLC.: KEY FINANCIALS
FIGURE 16 ALLERGAN PLC: SEGMENTAL REVENUE
FIGURE 17 ALLERGAN PLC: REGIONAL REVENUE
FIGURE 18 PFIZER INC.: KEY FINANCIALS
FIGURE 19 PFIZER INC.: SEGMENTAL REVENUE
FIGURE 20 PFIZER INC.: REGIONAL REVENUE
FIGURE 21 GLAXOSMITHKLINE PLC: KEY FINANCIALS
FIGURE 22 GLAXOSMITHKLINE PLC: SEGMENTAL REVENUE
FIGURE 23 GLAXOSMITHKLINE PLC: REGIONAL REVENUE
FIGURE 24 MERCK & CO., INC. KEY FINANCIALS
FIGURE 25 MERCK & CO., INC.: SEGMENTAL REVENUE
FIGURE 26 MERCK & CO., INC.: REGIONAL REVENUE
FIGURE 27 TEVA PHARMACEUTICALS INDUSTRIES LTD: KEY FINANCIALS
FIGURE 28 TEVA PHARMACEUTICALS INDUSTRIES LTD: SEGMENTAL REVENUE
FIGURE 29 TEVA PHARMACEUTICALS INDUSTRIES LTD: REGIONAL REVENUE
FIGURE 30 ASTRAZENECA PLC: KEY FINANCIALS
FIGURE 31 ASTRAZENECA PLC: SEGMENTAL REVENUE
FIGURE 32 ASTRAZENECA PLC: REGIONAL REVENUE
FIGURE 33 JOHNSON & JOHNSON SERVICES, INC.: KEY FINANCIALS
FIGURE 34 JOHNSON & JOHNSON SERVICES, INC.: SEGMENTAL REVENUE
FIGURE 35 JOHNSON & JOHNSON SERVICES, INC.: REGIONAL REVENUE
FIGURE 36 AMGEN INC: KEY FINANCIALS
FIGURE 37 AMGEN INC: SEGMENTAL REVENUE
FIGURE 38 AMGEN INC: REGIONAL REVENUE
FIGURE 39 ELI LILLY AND COMPANY: KEY FINANCIALS
FIGURE 40 ELI LILLY AND COMPANYSEGMENTAL REVENUE
FIGURE 41 ELI LILLY AND COMPANY: REGIONAL REVENUE
FIGURE 42 ENERA INC: KEY FINANCIALS
FIGURE 43 ENERA INC: SEGMENTAL REVENUE
FIGURE 44 ENERA INC: REGIONAL REVENUE
